Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Telix Pharmaceuticals Ltd. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's prostate cancer therapeutic candidates and supply chain quality [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from February 21, 2025, to August 28, 2025 [1]. - The complaint claims that defendants overstated the progress of Telix's prostate cancer therapeutic candidates and the quality of its supply chain and partners [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of TLX during the specified timeframe are encouraged to register for the class action by January 9, 2026 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. Lawsuit - TLX